Page 7,101«..1020..7,1007,1017,1027,103..7,1107,120..»

Editor’s move sparks backlash

Posted: Published on February 22nd, 2012

Bioethicist Glenn McGee’s new job raised questions of conflict of interest at the journal he founded. J. WILSON/KRT/NEWSCOM The field of bioethics is embroiled in a period of soul-searching, sparked by a startling career move by one of its biggest names. Glenn McGee is the editor-in-chief of the American Journal of Bioethics (AJOB), the most cited bioethics journal, which he founded in 1999. Since December 2011, he has also been president for ethics and strategic initiatives at CellTex Therapeutics in Houston, Texas, a controversial company involved in providing customers with unproven stem-cell therapies. A CellTex press release says that “Dr McGee’s responsibilities will include ensuring that all of the firm’s work, centered on adult stem cells, will meet the highest ethical standards of the medical and scientific communities.” Although McGee has said he will leave the journal on 1 March, many bioethicists have criticized him, the journal’s editorial board and its publisher, London-based Taylor and Francis. They argue that in holding both posts, McGee has a conflict of interest between his responsibilities to the journal and his new employer’s desire to promote the clinical application of stem-cell treatments that are not approved by the US Food and Drug Administration. “Imagine … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Editor’s move sparks backlash

InVivo Therapeutics Prices 8.2M Shares Offering

Posted: Published on February 22nd, 2012

More Topics: Choose a Sector Accounting Firms Advertising/Media/Communications Capital CEO/Board General Business Health/Biotech Internet/Technology Investment Firms Law Firms Mergers & Acquisitions Money Managers People Private Companies Public Companies Venture Capital Posted February 21, 2012 CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries, today announced the pricing of an underwritten public offering of 8,281,574 shares of its common stock, offered at a price to the public of $2.10 per share, for gross proceeds of approximately $17.4 million. Net proceeds to InVivo, after deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $15.7 million. InVivo anticipates using the net proceeds from the offering for working capital and other general corporate purposes, including the research, development and pre-clinical and clinical trials for its product candidates, capital expenditures, repayment of debt and possibly acquisitions of other businesses, products or technologies. In addition, InVivo has granted the underwriters an option to purchase up to an additional 1,242,236 shares of its common stock to cover overallotments, if any. The offering is expected to close on or about February 23, 2012, subject to customary closing conditions. Aegis Capital Corp. and … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on InVivo Therapeutics Prices 8.2M Shares Offering

InVivo Therapeutics Announces Net $18.1M In Offering

Posted: Published on February 22nd, 2012

More Topics: Choose a Sector Accounting Firms Advertising/Media/Communications Capital CEO/Board General Business Health/Biotech Internet/Technology Investment Firms Law Firms Mergers & Acquisitions Money Managers People Private Companies Public Companies Venture Capital Posted February 21, 2012 CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries, today announced the full exercise of the over-allotment option granted to the underwriters to purchase 1,242,236 additional shares, at a public offering price of $2.10 per share, in connection with its previously announced underwritten public offering of 8,281,574 shares, bringing aggregate gross proceeds from the offering to $20 million dollars. Net proceeds to InVivo, after deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $18.1 million. The offering is expected to close on or about February 23, 2012, subject to customary closing conditions. Aegis Capital Corp. and Summer Street Research Partners are acting as joint book-running managers for the offering. About InVivo Therapeutics InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on InVivo Therapeutics Announces Net $18.1M In Offering

InVivo Therapeutics Announces Full Exercise of Over-Allotment Option

Posted: Published on February 22nd, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries, today announced the full exercise of the over-allotment option granted to the underwriters to purchase 1,242,236 additional shares, at a public offering price of $2.10 per share, in connection with its previously announced underwritten public offering of 8,281,574 shares, bringing aggregate gross proceeds from the offering to $20 million dollars. Net proceeds to InVivo, after deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $18.1 million. The offering is expected to close on or about February 23, 2012, subject to customary closing conditions. Aegis Capital Corp. and Summer Street Research Partners are acting as joint book-running managers for the offering. The securities described above are being offered by InVivo pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the “SEC”), which the SEC declared effective on January 19, 2012. A final prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering, when … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on InVivo Therapeutics Announces Full Exercise of Over-Allotment Option

Experimental Drug Helps Reduce Brain Injury

Posted: Published on February 22nd, 2012

Experimental Drug Helps Reduce Brain Injury A drug that targets blood vessels in the brain shows promise in animal tests. Wednesday, February 22, 2012 By Courtney Humphries It's estimated that five million people in the U.S. suffer from the long-term effects of traumatic brain injury (TBI)—which can range from coma to loss of movement to cognitive and behavioral problems. A large percentage of soldiers injured in Iraq and Afghanistan have sustained some form of TBI. Scientists have been searching for years for drugs that could ameliorate the effects of these injuries, but so far, none have been shown to prevent damage or speed healing. Researchers at Wayne State University in Detroit are investigating a drug that they hope could prevent the damage of TBI by improving blood flow to the brain. So far, the drug, called clazosentan, has shown promise in animal tests in improving recovery after a blow to the head. Christian Kreipke, the lead author of a study describing the tests, says that most experimental TBI treatments have targeted two problems in the injured brain: dangerous swelling of the brain, and structural damage to neurons. In contrast, his team is trying to prevent a third side effect of … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Experimental Drug Helps Reduce Brain Injury

Multiple Sclerosis treatment a challenge in India? – Video

Posted: Published on February 22nd, 2012

20-02-2012 23:55 One in a lakh Indians is thought to suffer from multiple sclerosis, a life-long disorder of the nervous system. Support groups are lobbying to bring the disease under the Disability Act, and are fighting for insurance cover. ibnlive.com See the article here: Multiple Sclerosis treatment a challenge in India? - Video … Continue reading →

Posted in MS Treatment | Comments Off on Multiple Sclerosis treatment a challenge in India? – Video

Cleveland Clinic physician receives prominent award for outstanding contributions to MS research

Posted: Published on February 22nd, 2012

Public release date: 21-Feb-2012 [ | E-mail | Share ] Contact: Dan Doron dorond@ccf.org 216-636-5874 Cleveland Clinic Tuesday, February 21, 2012, Cleveland: Richard Ransohoff, M.D., a Cleveland Clinic physician and a researcher in the Neurosciences Department of Cleveland Clinic's Lerner Research Institute, has been awarded the 2012 John Dystel Prize for Multiple Sclerosis Research. The award ? presented by the American Academy of Neurology (AAN) and the National Multiple Sclerosis Society since 1995 ? is given annually to one recipient, recognizing "outstanding contributions to research in the understanding, treatment, or prevention of multiple sclerosis" and "significant and exciting work that has influenced how we think about multiple sclerosis." Dr. Ransohoff's most recent contributions to the field of multiple sclerosis (MS) include the discovery that MS can progress from the outermost layers of the brain to its interior. Aiming to lower the risk/benefit ratio of multiple sclerosis therapy, he has also recently developed an experimental model that allowed his group to identify a novel mechanism for harmful infiltration of white blood cells into the central nervous system. With increased understanding of this process and how it is regulated, new therapeutic targets are possible. "It is an honor to receive this award, … Continue reading →

Posted in MS Treatment | Comments Off on Cleveland Clinic physician receives prominent award for outstanding contributions to MS research

Cognitive rehabilitation improves brain performance in patients with MS

Posted: Published on February 22nd, 2012

Public release date: 22-Feb-2012 [ | E-mail | Share ] Contact: Linda Brooks lbrooks@rsna.org 630-590-7762 Radiological Society of North America OAK BROOK, Ill. ? In a new study published in the March issue of Radiology, functional magnetic resonance imaging (fMRI) shows that cognitive rehabilitation changes brain function and improves cognitive performance in patients with relapsing-remitting multiple sclerosis (MS). "These results prompt the use of specific computer-based rehabilitation programs to treat deficits in selected neuropsychological domains in patients with relapsing-remitting MS," said the study's lead author, Massimo Filippi, M.D., professor of neurology at the San Raffaele Vita-Salute University and director of the "BrainMap" interdepartmental research program and the Neuroimaging Research Unit, Department of Neuroscience, Scientific Institute San Raffaele, Milan, Italy. "They also suggest that fMRI might provide useful metrics to monitor the effects of rehab in MS." MS is a nervous system disease affecting the brain and spinal cord. MS damages a material called the myelin sheath that surrounds and protects nerve cells. This damage disrupts messages between the brain and other parts of the body, leading to symptoms such as muscle weakness, coordination and balance difficulties, numbness, problems with vision, memory loss and other cognitive issues. MS affects women more … Continue reading →

Posted in MS Treatment | Comments Off on Cognitive rehabilitation improves brain performance in patients with MS

Qatari students to present research on stem cells

Posted: Published on February 22nd, 2012

Research on the potential of stem cells in preventing ovarian cancer, obesity-related diseases and other serious illnesses affecting people in Qatar and the region is to be presented by three Qatari graduate students at the Qatar International Conference on Stem Cell Science and Policy next week. The conference is organised by Qatar Foundation for Education, Science and Community Development (QF) and James A Baker III Institute for Public Policy. It will provide an international platform to discuss the latest discoveries in stem cell research and collaborate on new therapeutic approaches for the use of stem cells, within an acceptable ethics, cultural and religious framework. The students are part of QF’s Qatar Science Leadership Programme (QSLP), and their participation in the conference is considered an important part of their training.  With more than 400 registered participants, including key ethicists and scientists in stem cell research, the conference provides students invaluable opportunities for exchanging knowledge and building relationships with top figures and leading regional and international institutions in the field. QSLP, aims to equip rising Qatari generations for leading roles in the country’s scientific and research endeavours, with stem cell research as a national priority. Qatari QSLP trainee and PhD student from … Continue reading →

Posted in Stem Cell Research | Comments Off on Qatari students to present research on stem cells

Stem cell implants boost monkeys with Parkinson's

Posted: Published on February 22nd, 2012

Monkeys suffering from Parkinson's disease show a marked improvement when human embryonic stem cells are implanted in their brains, in what a Japanese researcher said Wednesday was a world first. A team of scientists transplanted the stem cells into four primates that were suffering from the debilitating disease. The monkeys all had violent shaking in their limbs -- a classic symptom of Parkinson's disease -- and were unable to control their bodies, but began to show improvements in their motor control after about three months, Kyoto University associate professor Jun Takahashi told AFP. About six months after the transplant, the creatures were able to walk around their cages, he said. "Clear improvements were confirmed in their movement," he said. Parkinson's disease is a progressive neurological illness linked to a decrease in dopamine production in the brain. There is currently no medical solution to this drop off in a key neurotransmitter. The condition, which generally affects older people, gained wider public recognition when Hollywood actor Michael J. Fox revealed he was a sufferer. Takahashi said at the time of the implant about 35 percent of the stem cells had already grown into dopamine neuron cells, with around 10 percent still alive … Continue reading →

Posted in Stem Cell Research | Comments Off on Stem cell implants boost monkeys with Parkinson's

Page 7,101«..1020..7,1007,1017,1027,103..7,1107,120..»